Talphera to Host Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update Call and Webcast on Monday, March 31, 2025
Talphera (NASDAQ: TLPH) has announced it will release its fourth quarter and full-year 2024 financial results after market close on Monday, March 31, 2025. The specialty pharmaceutical company, focused on developing innovative therapies for medically supervised settings, will host a live webcast and conference call at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Standard.
The webcast will feature a slide presentation and can be accessed through the company's website at www.talphera.com in the Investors/News & Events/Upcoming Events section. A replay will be available for 90 days following the event. Investors can join the conference call by dialing 1-800-836-8184 (North America) or 1-646-357-8785 (international) using conference ID 11814.
Talphera (NASDAQ: TLPH) ha annunciato che pubblicher脿 i suoi risultati finanziari del quarto trimestre e dell'intero anno 2024 dopo la chiusura del mercato luned矛 31 marzo 2025. L'azienda farmaceutica specializzata, focalizzata sullo sviluppo di terapie innovative per contesti medici supervisionati, ospiter脿 un webcast dal vivo e una conferenza telefonica alle 16:30 ora orientale/13:30 ora del Pacifico.
Il webcast presenter脿 una presentazione con diapositive e sar脿 accessibile attraverso il sito web dell'azienda all'indirizzo www.talphera.com nella sezione Investitori/Notizie & Eventi/Eventi Futuri. Una registrazione sar脿 disponibile per 90 giorni dopo l'evento. Gli investitori possono partecipare alla conferenza telefonica componendo il numero 1-800-836-8184 (Nord America) o 1-646-357-8785 (internazionale) utilizzando l'ID conferenza 11814.
Talphera (NASDAQ: TLPH) ha anunciado que publicar谩 sus resultados financieros del cuarto trimestre y del a帽o completo 2024 despu茅s del cierre del mercado el lunes 31 de marzo de 2025. La compa帽铆a farmac茅utica especializada, centrada en desarrollar terapias innovadoras para entornos m茅dicos supervisados, llevar谩 a cabo una transmisi贸n en vivo y una conferencia telef贸nica a las 4:30 p.m. hora del este/1:30 p.m. hora del pac铆fico.
La transmisi贸n incluir谩 una presentaci贸n de diapositivas y se podr谩 acceder a trav茅s del sitio web de la compa帽铆a en www.talphera.com en la secci贸n Inversores/Noticias y Eventos/Eventos Futuros. Se dispondr谩 de una grabaci贸n durante 90 d铆as despu茅s del evento. Los inversores pueden unirse a la conferencia telef贸nica marcando el 1-800-836-8184 (Am茅rica del Norte) o el 1-646-357-8785 (internacional) utilizando el ID de conferencia 11814.
韮堩帢霛� (NASDAQ: TLPH)电� 2024雲� 4攵勱赴 氚� 鞐瓣皠 鞛 瓴瓣臣毳� 2025雲� 3鞗� 31鞚� 鞗旍殧鞚� 鞁滌灔 膦呺 頉� 氚滍憸頃� 瓴冹澊霛缄碃 氚滍憸頄堨姷雼堧嫟. 順侅嫚鞝侅澑 旃橂氩� 臧滊皽鞐� 欤茧牓頃樀鐢 鞝勲 鞝滌暯 須岇偓电� 霃欕秬 響滌鞁� 旮办 鞓ろ泟 4鞁� 30攵�/韮滍弶鞏� 響滌鞁� 旮办 鞓ろ泟 1鞁� 30攵勳棎 霛检澊敫� 鞗轨簮鞀ろ姼鞕� 旎嵓霟办姢 旖滌潉 歆勴枆頃� 鞓堨爼鞛呺媹雼�.
鞗轨簮鞀ろ姼电� 鞀澕鞚措摐 頂勲爤鞝犿厡鞚挫厴鞚� 韽暔頃橂┌, 須岇偓 鞗轨偓鞚错姼 www.talphera.com鞚� 韴瀽鞛�/雺挫姢 氚� 鞚措菠韸�/鞓堨爼霅� 鞚措菠韸� 靹轨厴鞚� 韱淀暣 鞝戧芳頃� 靾� 鞛堨姷雼堧嫟. 鞚措菠韸� 鞚错泟 90鞚� 霃欖晥 鞛儩鞚� 臧�電ロ暕雼堧嫟. 韴瀽鞛惖鐢 1-800-836-8184(攵侂) 霕惖鐢 1-646-357-8785(甑牅)搿� 鞝勴檾頃橃棳 旎嵓霟办姢 ID 11814毳� 靷毄頃橃棳 旎嵓霟办姢 旖滌棎 彀胳棳頃� 靾� 鞛堨姷雼堧嫟.
Talphera (NASDAQ: TLPH) a annonc茅 qu'elle publiera ses r茅sultats financiers du quatri猫me trimestre et de l'ann茅e compl猫te 2024 apr猫s la fermeture du march茅 le lundi 31 mars 2025. L'entreprise pharmaceutique sp茅cialis茅e, ax茅e sur le d茅veloppement de th茅rapies innovantes pour des environnements m茅dicalement supervis茅s, organisera un webcast en direct et une conf茅rence t茅l茅phonique 脿 16h30 heure de l'Est/13h30 heure du Pacifique.
Le webcast comprendra une pr茅sentation par diapositive et sera accessible via le site web de l'entreprise 脿 l'adresse www.talphera.com dans la section Investisseurs/Nouvelles & 脡v茅nements/脡v茅nements 脿 venir. Un enregistrement sera disponible pendant 90 jours apr猫s l'茅v茅nement. Les investisseurs peuvent rejoindre la conf茅rence t茅l茅phonique en composant le 1-800-836-8184 (Am茅rique du Nord) ou le 1-646-357-8785 (international) en utilisant l'ID de conf茅rence 11814.
Talphera (NASDAQ: TLPH) hat bekannt gegeben, dass die Finanzergebnisse f眉r das vierte Quartal und das gesamte Jahr 2024 nach B枚rsenschluss am Montag, dem 31. M盲rz 2025, ver枚ffentlicht werden. Das auf die Entwicklung innovativer Therapien f眉r medizinisch 眉berwachte Umgebungen spezialisierte Pharmaunternehmen wird um 16:30 Uhr Eastern Time/13:30 Uhr Pacific Standard eine Live-Webcast- und Telefonkonferenz veranstalten.
Der Webcast wird eine Pr盲sentation mit Folien enthalten und kann 眉ber die Website des Unternehmens unter www.talphera.com im Abschnitt Investoren/Nachrichten & Veranstaltungen/Zuk眉nftige Veranstaltungen aufgerufen werden. Eine Aufzeichnung wird 90 Tage nach der Veranstaltung verf眉gbar sein. Investoren k枚nnen an der Telefonkonferenz teilnehmen, indem sie 1-800-836-8184 (Nordamerika) oder 1-646-357-8785 (international) anrufen und die Konferenz-ID 11814 verwenden.
- None.
- None.
SAN聽MATEO, Calif., March 26, 2025 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release fourth quarter and full-year 2024 financial results after market close on Monday, March 31, 2025, then host a live webcast and conference call at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Standard to discuss the results and provide an update on the Company's business.
Webcast Information
The webcast can be accessed 聽or by visiting the Investors section of the Company's website at www.talphera.com聽and clicking on the webcast link posted within Investors/News & Events/Upcoming Events section. The webcast will include a slide presentation and a replay will be available on the Talphera website for 90 days following the event.
Conference Call Information
Investors who wish to participate in the conference call may do so by dialing 1-800-836-8184 for North American callers, or 1-646-357-8785 (toll applies) for international callers outside of
About Talphera, Inc.
Talphera, Inc.聽is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. Talphera's lead product candidate, Niyad鈩� is a lyophilized formulation of nafamostat and is currently being studied under an investigational device exemption (IDE) as an anticoagulant for the extracorporeal circuit, and has received Breakthrough Device Designation status from the
This release is intended for investors only. For additional information about Talphera, please visit聽www.talphera.com.
View original content to download multimedia:
SOURCE Talphera, Inc.
FAQ
When will Talphera (TLPH) release its Q4 and full-year 2024 earnings?
What time is Talphera's (TLPH) Q4 2024 earnings call?
How can investors access Talphera's (TLPH) Q4 2024 earnings webcast?
What is the conference call dial-in number for Talphera's (TLPH) Q4 2024 earnings?
